AmericanHHM
Pentamed® - High performance packaging films for medical devices

Caristo Diagnostics Introduces Cutting-Edge Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Thursday, July 13, 2023

Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, has announced the deployment of its latest CaRi-Heart® technology in several UK NHS hospitals. This initiative is part of a pilot program focused on managing coronary artery disease (CAD). The pilot, supported by NHS England, involves five NHS trusts: University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.

The pilot program aims to optimize medical management and improve the assessment of cardiac risk in patients visiting Rapid Access Chest Pain Clinics (RACPCs) who undergo a CCTA scan, following NICE guidance. The scans will be analyzed using the CaRi-Heart platform, which is capable of detecting coronary inflammation and atherosclerosis (plaque) based on routine cardiac CT scans.

The CaRi-Heart platform includes the CaRi-PlaqueTM module, a web-based software medical device that allows trained operators to analyze cardiac computed tomography angiography (CCTA) data for coronary plaque characterization and quantification. Powered by artificial intelligence (AI) algorithms, the CaRi-Plaque module generates reports describing the physical characteristics of coronary plaque.

One significant feature of the CaRi-Heart report is the measurement of coronary inflammation using the patient-specific Fat Attenuation Index ScoreTM (FAI ScoreTM), a patented biomarker. The report also provides the CaRi-Heart Risk, which assesses the 8-year risk of a fatal heart attack based on coronary inflammation status, plaque, and clinical risk factors. Research studies have shown that abnormal FAI scores are associated with a significantly higher risk of fatal and non-fatal heart attacks.

By incorporating the CaRi-Heart analysis into the diagnostic process, healthcare professionals can identify at-risk patients more effectively and optimize their treatment plans, potentially preventing future cardiac events. The advanced AI algorithms utilized by the CaRi-Heart technology allow for improved risk prediction and better diagnosis of coronary artery disease.

The deployment of CaRi-Heart technology in UK NHS hospitals represents a significant step forward in cardiac disease diagnostics and risk management, with the potential to enhance patient outcomes and reduce the burden of cardiovascular disease.

 

Source: prnewswire.com

Healthcare CEO & Executive Strategy SummitNational Healthcare CMO Summit USANational Healthcare CNO Summit USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitACO Leadership Summit